Not actual patients.
An innovative approach
How HYMPAVZI works
HYMPAVZI is designed to help achieve balance in the clotting process—independent of factor VIII or IX levels—by targeting TFPI.
Why is achieving balance important?
In people without hemophilia, anticlotting factors and clotting factors work in balance like a scale so the body can clot when needed—without causing too much clotting or too much bleeding.
In people with hemophilia, a lack of clotting factors causes the scale to tip toward bleeding.
HYMPAVZI works to help achieve this balance.
How does it work?
HYMPAVZI uses an innovative approach that may help achieve the balance by targeting TFPI to decrease anticlotting activity.
Blocking the activity of TFPI increases the tendency to develop thrombin, which may improve clotting function.
This could potentially help the body prevent or reduce the frequency of bleeding episodes.
HYMPAVZI helps your body make the thrombin needed to help form a clot.
APC=activated protein C; AT=antithrombin; TFPI=tissue factor pathway inhibitor. These do not represent all of the anticlotting and clotting factors in the body.
Watch this video to learn more about HYMPAVZI at work
video_id
6405090953112
account_id
1852113022001
loop
false
title
How HYMPAVZI® works video
poster
Meet the once-weekly, fixed-dose* pens
- HYMPAVZI is available in 75 mg and 150 mg pens. For children ages 6 to less than 12, the first dose (loading dose) is 150 mg on day 1. Then a weekly (maintenance) dose of 75 mg as prescribed by your healthcare provider. For adults and adolescents 12+, the first dose (loading dose) is 300 mg on day 1. Then a weekly (maintenance) dose of 150 mg as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different site.
HYMPAVZI has been studied in 2 clinical trials. See study results.
See the HYMPAVZI study design